INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of... It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.
- Mechanism
- Curator reviewed
INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. Currently approved therapies that target the EGFR pathways have shown promising efficacy in metastatic disease, validating these pathways as targets; however, efficacy may be limited due to the fact that these drugs inhibit only one or two of the four HER receptor pathways. In contrast, the sheddase inhibitor, INCB7839, has the potential to inhibit activation through all four of the HER receptors, resulting in more complete inhibition of these pathways.
- Primary indication
- Investigated for use/treatment in breast cancer.Curator reviewed
- Code names
- INCB7839
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with INCB7839, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account